On Jan 09, major Wall Street analysts update their ratings for $Jasper Therapeutics (JSPR.US)$, with price targets ranging from $40 to $80.
BMO Capital analyst Etzer Darout maintains with a buy rating, and maintains the target price at $63.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $80.
Stifel analyst Benjamin Burnett maintains with a buy rating, and maintains the target price at $80.
BTIG analyst Justin Zelin maintains with a buy rating, and adjusts the target price from $90 to $64.
RBC Capital analyst Gregory Renza maintains with a buy rating, and adjusts the target price from $68 to $48.
Furthermore, according to the comprehensive report, the opinions of $Jasper Therapeutics (JSPR.US)$'s main analysts recently are as follows:
The sharp decline in Jasper Therapeutics' stock following initial data from BEACON highlights the current market's low tolerance for uncertainties within biotech sectors. While the data could have been stronger, the response seems excessive given the positive efficacy signals at 240mg and preliminary safety profiles. Better understanding of briquilimab's advantages and risks at future doses could potentially recalibrate the stock's valuation. The assessment of briquilimab's role in treating chronic spontaneous urticaria is still developing.
Following the recent presentation of data from the Phase 1b/2a BEACON study in chronic spontaneous urticaria, it has been noted that briquilimab proves active and efficacious in treating the condition, demonstrating a favorable early safety profile. Despite these positive findings, the stock has significantly declined. This is attributed to perceptions that briquilimab's market differentiation compared to competing treatments like Celldex's barzolvolimab is less significant. Future potential updates that could impact the stock include additional BEACON study data and preliminary asthma treatment data expected later this year.
Here are the latest investment ratings and price targets for $Jasper Therapeutics (JSPR.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間1月9日，多家華爾街大行更新了$Jasper Therapeutics (JSPR.US)$的評級，目標價介於40美元至80美元。
BMO資本市場分析師Etzer Darout維持買入評級，維持目標價63美元。
奧本海默控股分析師Jay Olson維持買入評級，維持目標價80美元。
斯迪富分析師Benjamin Burnett維持買入評級，維持目標價80美元。
BTIG分析師Justin Zelin維持買入評級，並將目標價從90美元下調至64美元。
加皇資本市場分析師Gregory Renza維持買入評級，並將目標價從68美元下調至48美元。
此外，綜合報道，$Jasper Therapeutics (JSPR.US)$近期主要分析師觀點如下：
雅斯珀治療公司的股票因BEACON初步數據而急劇下降，這凸顯了當前市場對生物技術行業不確定性的低容忍度。儘管數據本可以更強，但考慮到240mg的積極療效信號和初步安全性資料，反應似乎過於激烈。更好地理解briquilimab在未來劑量中的優勢和風險可能會重新調整股票的估值。briquilimab在治療慢性自發性蕁麻疹中的作用評估仍在發展中。
在近期慢性自發性蕁麻疹的1b/2a期BEACON研究數據發佈後，已注意到briquilimab在治療該控制項中活躍且有效，顯示出良好的早期安全性資料。儘管這些積極的發現，股票卻顯著下跌。這歸因於對briquilimab與競爭治療（如Celldex的barzolvolimab）相比，其市場差異化程度的認知不足。未來可能影響股票的更新包括BEACON研究的附加數據以及預計在今年晚些時候發佈的初步哮喘治療數據。
以下爲今日7位分析師對$Jasper Therapeutics (JSPR.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
